[Study on recombinant BCG].
The progress of study on recombinant BCG was stated briefly. And then our studies on recombinant BCG were mentioned. Recombinant BCG secreting alpha antigen-fused merozoite surface protein 1 (MSP 1) was prepared and tested for its ability to control infections of Plasmodium yoelii. Result turned out it controlled the infection better than recombinant MSP 1 mixed with Freund incomplete adjuvant did. Recombinant BCG secreting excess amounts of antigen 85 complex A controlled infection of Mycobacterium leprae. Addition of recombinant BCG secreting alpha antigen-fused IL-2 to peritoneal exudate cells induced IFN-gamma resulting in killing bladder cancer cells more efficiently than parental BCG did.
Yamada
T
T
Nagasaki University, Japan.
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D020558:GTP Phosphohydrolases; D006801:Humans; D007918:Leprosy / Q000517:prevention & control; D017780:Malaria Vaccines; D020066:Merozoite Surface Protein 1; D009163:Mycobacterium bovis; D011994:Recombinant Proteins; D014376:Tuberculosis / Q000517:prevention & control; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control / Q000628:therapy
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D017780:Malaria Vaccines; D020066:Merozoite Surface Protein 1; D011994:Recombinant Proteins; D020558:GTP Phosphohydrolases